Pieter Cullis

Q: What Schools Are Affiliated With Pieter Cullis

Pieter Cullis is affiliated with the following schools: University of Oxford, University of Alberta, University of British Columbia

Pieter Cullis's AcademicInfluence.com Rankings

Pieter Cullis

Biology

#3247

World Rank

#4987

Historical Rank

Molecular Biology

#239

World Rank

#243

Historical Rank

Biochemistry

#328

World Rank

#398

Historical Rank

biology Degrees

Download Badge

Biology

Pieter Cullis's Degrees

PhD Biochemistry University of British Columbia
Bachelors Chemistry University of British Columbia

Why Is Pieter Cullis Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Pieter Rutter Cullis is a Canadian physicist and biochemist known for his contributions to the field of lipid nanoparticles . Lipid nanoparticles are essential to current mRNA vaccines as a delivery system. Prof. Cullis is best known for the development of ionizable cationic lipids. These lipids are able to complex with negatively charged nucleic acids at low pH where they are positively charged because they have a pKa if approximately 6.4. They reduce or eliminate toxicity associated with cationic lipids at physiological pH of 7.4 because they adopt a net neutral charge. Finally, they enable endosomal escape because they again become positively charged in acidified endosomes and promote formation of non-bilayer structures by interaction with negatively charged lipids. These properties are critical to the function of the mRNA vaccines and are rapidly enabling gene therapy in clinical settings.

(See a Problem?)

Pieter Cullis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Drug Delivery Systems: Entering the Mainstream (2004) (3977)
Liposomal drug delivery systems: from concept to clinical applications. (2013) (3338)
Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. (1985) (2000)
Lipid polymorphism and the functional roles of lipids in biological membranes. (1979) (1684)
Vesicles of variable sizes produced by a rapid extrusion procedure. (1986) (1572)
Rational design of cationic lipids for siRNA delivery (2010) (1249)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** (2012) (726)
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs (2019) (502)
Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. (1992) (434)
Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. (1985) (433)
Lipid Nanoparticle Systems for Enabling Gene Therapies. (2017) (431)
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA (2012) (397)
The polymorphic phase behaviour of phosphatidylethanolamines of natural and synthetic origin. A 31P NMR study. (1978) (386)
Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. (1989) (373)
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. (1986) (354)
Lipid polymorphism and the roles of lipids in membranes. (1986) (346)
The liposomal formulation of doxorubicin. (2005) (345)
Generation of multilamellar and unilamellar phospholipid vesicles (1986) (341)
The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. (1991) (330)
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. (2001) (320)
Developments in liposomal drug delivery systems (2001) (319)
Polymorphic phase behaviour of lipid mixtures as detected by 31P NMR. Evidence that cholesterol may destabilize bilayer structure in membrane systems containing phosphatidylethanolamine. (1978) (317)
Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. (2013) (310)
Effects of fusogenic agent on membrane structure of erythrocyte ghosts and the mechanism of membrane fusion (1978) (282)
Lipid polymorphism: the molecular basis of nonbilayer phases. (1985) (260)
Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility. (2018) (260)
The current landscape of nucleic acid therapeutics (2021) (258)
Influence of cholesterol on the association of plasma proteins with liposomes. (1996) (243)
Liposome-complement interactions in rat serum: implications for liposome survival studies. (1994) (243)
Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. (2012) (241)
Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. (1990) (238)
The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. (1990) (237)
X-ray diffraction study of the polymorphic behavior of N-methylated dioleoylphosphatidylethanolamine. (1988) (236)
Unusual lipid structures selectively reduce the toxicity of amphotericin B. (1988) (209)
On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA. (2018) (208)
Cytochrome c specifically induces non-bilayer structures in cardiolipin-containing model membranes. (1980) (207)
Recent advances in liposomal drug-delivery systems. (1995) (206)
Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. (1997) (206)
Chapter 1 Physical properties and functional roles of lipids in membranes (1991) (206)
Polymorphic phase behaviour of cardiolipin as detected by 31P NMR and freeze-fracture techniques. Effects of calcium, dibucaine and chlorpromazine. (1978) (205)
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles (2013) (195)
Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. (2001) (194)
Osmotic properties of large unilamellar vesicles prepared by extrusion. (1993) (192)
Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. (1985) (191)
Smoothed orientational order profile of lipid bilayers by 2H-nuclear magnetic resonance. (1989) (188)
Effects of tumbling and lateral diffusion on phosphatidylcholine model membrane 31P-NMR lineshapes. (1980) (188)
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core (2012) (185)
Liposomal nanomedicines (2008) (184)
Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. (1996) (183)
Generation of large unilamellar vesicles from long-chain saturated phosphatidylcholines by extrusion technique (1989) (182)
Techniques for encapsulating bioactive agents into liposomes. (1986) (181)
β2-Glycoprotein I Is a Major Protein Associated with Very Rapidly Cleared Liposomes in Vivo, Suggesting a Significant Role in the Immune Clearance of "Non-self" Particles (*) (1995) (181)
Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. (2005) (180)
Use of liposomes as injectable-drug delivery systems. (1989) (177)
Differential scanning calorimetry and 31P NMR studies on sonicated and unsonicated phosphatidylcholine liposomes. (1975) (177)
31P NMR studies of unsonicated aqueous dispersions of neutral and acidic phospholipids. Effects of phase transitions, p2H and divalent cations on the motion in the phosphate region of the polar headgroup. (1976) (176)
Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. (2005) (173)
Fusion of phospholipid vesicles in association with the appearance of lipidic particles as visualized by freeze fracturing. (1979) (168)
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics. (2019) (165)
The Cellular Mechanisms of Neuronal Swelling Underlying Cytotoxic Edema (2015) (164)
Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery. (2019) (163)
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. (1998) (157)
Phospholipids and membrane transport. (1980) (156)
Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. (1993) (156)
Advances in Lipid Nanoparticles for siRNA Delivery (2013) (156)
Tunable pH-sensitive liposomes composed of mixtures of cationic and anionic lipids. (2000) (149)
Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. (1982) (149)
Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems. (2015) (147)
Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. (1985) (146)
Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells (2011) (144)
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. (2016) (144)
Structural and fusogenic properties of cationic liposomes in the presence of plasmid DNA. (1997) (143)
Liposomal Nanomedicines: An Emerging Field (2008) (141)
The lipidic particle as an intermediate structure in membrane fusion processes and bilayer to hexagonal HII transitions. (1980) (139)
Lateral diffusion rates of phosphatidylcholine in vesicle membranes: Eeffects of cholesterol and hydrocarbon phase transitions (1976) (136)
Liposomal Gd-DTPA: preparation and characterization of relaxivity. (1989) (134)
Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. (1994) (132)
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. (2006) (132)
Lipid nanoparticle delivery systems for siRNA-based therapeutics (2014) (131)
Effects of divalent cations and pH on phosphatidylserine model membranes: a 31P NMR study. (1980) (130)
Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. (1994) (128)
Liposomes with entrapped doxorubicin exhibit extended blood residence times. (1990) (128)
Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). (1997) (126)
Membrane fusion with cationic liposomes: effects of target membrane lipid composition. (1997) (126)
Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. (1990) (124)
Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. (1991) (124)
Factors affecting the motion of the polar headgroup in phospholipid bilayers. A 31P NMR study of unsonicated phosphatidylcholine liposomes. (1976) (123)
Effects of cholesterol on the properties of equimolar mixtures of synthetic phosphatidylethanolamine and phosphatidylcholine. A 31P NMR and differential scanning calorimetry study. (1978) (122)
Lipid nanoparticle technology for therapeutic gene regulation in the liver (2020) (119)
Outside-inside distributions and sizes of mixed phosphatidylcholine-cholesterol vesicles. (1976) (118)
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain (2013) (118)
Influence of transbilayer area asymmetry on the morphology of large unilamellar vesicles. (1995) (117)
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. (2015) (117)
Influence of dose on liposome clearance: critical role of blood proteins. (1996) (116)
Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells (2012) (116)
Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. (1986) (115)
Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN (2007) (115)
Modulation of membrane structure by Ca2+ and dibucaine as detected by 31P NMR. (1979) (114)
Anomalous solubility behavior of the antibiotic ciprofloxacin encapsulated in liposomes: a 1H-NMR study. (1998) (111)
Non-bilayer lipid structures in model and biological membranes (1980) (109)
Protection of liposomes during dehydration or freezing. (1990) (109)
State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery (2018) (109)
Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties (1999) (107)
Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. (2007) (107)
Phospholipid asymmetry in large unilamellar vesicles induced by transmembrane pH gradients. (1989) (104)
Evidence for isotropic motion of phospholipids in liver microsomal membranes. A 31P NMR study. (1978) (101)
Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. (1990) (98)
Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles (1999) (97)
The polymorphic phase behavior of mixed phosphatidylserine-phosphatidylethanolamine model systems as detected by 31P-NMR. Effects of divalent cations and pH (1981) (95)
Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties. (1999) (94)
Stabilized plasmid-lipid particles for systemic gene therapy (2000) (94)
Ca2+ and pH induced fusion of small unilamellar vesicles consisting of phosphatidylethanolamine and negatively charged phospholipids: a freeze fracture study. (1983) (93)
Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA. (2017) (92)
The bilayer stabilizing role of sphingomyelin in the presence of cholesterol: a 31P NMR study. (1980) (92)
Stabilization of bilayer structure for unsaturated phosphatidylethanolamines by detergents. (1982) (92)
Influence of local and neutral anaesthetics on the polymorphic phase preferences of egg yolk phosphatidylethanolamine. (1981) (92)
Long-circulating vectors for the systemic delivery of genes. (2001) (91)
Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer-forming lipids. (1996) (91)
The role of nonbilayer lipid structures in the fusion of human erythrocytes induced by lipid fusogens. (1981) (90)
Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients. (1999) (90)
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. (2005) (89)
On the role of helper lipids in lipid nanoparticle formulations of siRNA. (2019) (89)
Lipid asymmetry induced by transmembrane pH gradients in large unilamellar vesicles. (1987) (88)
Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. (1994) (88)
Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration. (2014) (87)
Generating and loading of liposomal systems for drug-delivery applications (1989) (87)
Stabilized Plasmid–Lipid Particles: Pharmacokinetics and Plasmid Delivery to Distal Tumors following Intravenous Injection (2000) (86)
Lipid Nanoparticles for Short Interfering RNA Delivery (2014) (86)
Lipid-based systems for the intracellular delivery of genetic drugs. (1999) (84)
Optimization of the retention properties of vincristine in liposomal systems. (1993) (83)
The influence of poly(L-lysine) on phospholipid polymorphism. Evidence that electrostatic polypeptide-phospholipid interactions can modulate bilayer/non-bilayer transitions. (1980) (83)
Stabilized plasmid-lipid particles for systemic gene therapy. (2000) (81)
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. (2010) (81)
Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. (1998) (81)
Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin (2004) (77)
Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. (1984) (77)
Structural properties of phospholipids in the rat liver inner mitochondrial membrane. (1980) (76)
Chapter 2 – Structural Properties of Lipids and Their Functional Roles in Biological Membranes1 (1983) (75)
31P NMR of Phospholipid membranes: Effects of chemical and anisotropy at high magnetic field strengths (1975) (74)
Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. (1998) (74)
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo (2012) (74)
The polymorphic phase behaviour and miscibility properties of synthetic phosphatidylethanolamines (1982) (74)
A non-covalent method of attaching antibodies to liposomes. (1987) (74)
Calcium enhances the transfection potency of plasmid DNA-cationic liposome complexes. (2000) (72)
Transbilayer transport of phosphatidic acid in response to transmembrane pH gradients. (1991) (71)
Optimized procedures for the coupling of proteins to liposomes. (1990) (69)
Entrapment of small molecules and nucleic acid-based drugs in liposomes. (2005) (68)
Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. (2013) (67)
Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. (2007) (66)
Stabilized plasmid-lipid particles: a systemic gene therapy vector. (2002) (66)
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. (2006) (65)
Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia (2004) (65)
Acyl chain orientational order in the hexagonal HII phase of phospholipid-water dispersions. (1988) (63)
Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. (1993) (63)
Polymorphic phase preferences of phosphatidic acid: A 31P and 2H NMR study. (1983) (62)
Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. (1995) (61)
Polymorphism of phosphatidylglycerol-phosphatidylethanolamine model membrane systems: a 31p NMR study. (1980) (61)
The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy. (2020) (61)
Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor Efficacy (1995) (61)
Modulation of the orientational order profile of the lipid acyl chain in the Lα phase (2004) (60)
Preparation, characterization, and biological analysis of liposomal formulations of vincristine. (2005) (60)
Lipid polymorphism and membrane fusion. (1986) (58)
The Binding of Phosphatidylglycerol Liposomes to Rat Platelets Is Mediated by Complement (1990) (58)
Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes (1997) (57)
On the mechanism of transbilayer transport of phosphatidylglycerol in response to transmembrane pH gradients. (1990) (56)
Uptake of safranine and other lipophilic cations into model membrane systems in response to a membrane potential (1985) (56)
Non-bilayer structures in membrane fusion. (1984) (55)
Determination of the donor pair exchange energy in phosphorus-doped silicon (1970) (55)
Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. (1990) (55)
Influence of Drug-to-Lipid Ratio on Drug Release Properties and Liposome Integrity in Liposomal Doxorubicin Formulations (2008) (54)
Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes (2004) (54)
Liposomal doxorubicin. (1996) (54)
Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. (1988) (53)
The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin (1994) (52)
Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. (1993) (50)
31P-NMR studies on membrane phospholipids in microsomes, rat liver slices and intact perfused rat liver. (1980) (50)
Synthesis and properties of novel tetraalkyl cationic lipids. (2002) (50)
Correlation between lipid plane curvature and lipid chain order. (1996) (50)
pH-induced destabilization of lipid bilayers by a lipopeptide derived from influenza hemagglutinin. (1997) (47)
Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads. (2019) (47)
Ganglioside GM1 and Hydrophilic Polymers Increase Liposome Circulation Times by Inhibiting the Association of Blood Proteins (1992) (47)
Interactions of Liposomes and Platelets (1988) (46)
Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids. (2003) (46)
ON THE VALIDITY OF 31p-NMR DETERMINATIONS OF PHOSPHOLIPID POLYMORPHIC PHASE BEHAVIOUR (1986) (46)
Electron paramagnetic resonance properties ofn-type silicon in the intermediate impurity-concentration range (1975) (46)
siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer (2015) (46)
Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. (1989) (45)
Comparison of the orientational order of lipid chains in the L alpha and HII phases. (1990) (45)
Structural preferences of phosphatidylinositol and phosphatidylinositol-phosphatidylethanolamine model membranes. Influence of Ca2+ and Mg2+. (1982) (44)
Systemic study of solvent-assisted active loading of gambogic acid into liposomes and its formulation optimization for improved delivery. (2018) (44)
Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. (1985) (44)
-REDUCTION OF LIPOSOME SIZE AND PREPARATION OF UNILAMELLAR VESICLES BY EXTRUSION TECHNIQUES (2002) (43)
125I labelled inulin: a convenient marker for deposition of liposomal contents in vivo. (1984) (43)
Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. (1989) (41)
Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. (2009) (41)
Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. (1993) (40)
Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations (1998) (40)
Uptake of basic amino acids and peptides into liposomes in response to transmembrane pH gradients. (1992) (40)
Triggered release of doxorubicin following mixing of cationic and anionic liposomes. (2002) (40)
Influence of phospholipid asymmetry on fusion between large unilamellar vesicles. (1992) (40)
Influence of ion gradients on the transbilayer distribution of dibucaine in large unilamellar vesicles. (1988) (39)
Gadolinium-DTPA liposomes as a potential MRI contrast agent. Work in progress. (1988) (39)
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo (2019) (39)
Determination of transmembrane pH gradients and membrane potentials in liposomes. (1992) (38)
The Immunostimulatory Activity of Unmethylated and Methylated CpG Oligodeoxynucleotide Is Dependent on Their Ability To Colocalize with TLR9 in Late Endosomes (2010) (38)
Encapsulation of Plasmid DNA in Stabilized Plasmid – Lipid Particles Composed of Different Cationic Lipid Concentration for Optimal Transfection Activity (2000) (38)
Calcium-induced phase separation phenomena in multicomponent unsaturated lipid mixtures. (1988) (37)
The Niemann-Pick C1 Inhibitor NP3.47 Enhances Gene Silencing Potency of Lipid Nanoparticles Containing siRNA. (2016) (36)
Studies of highly asymmetric mixed-chain diacyl phosphatidylcholines that form mixed-interdigitated gel phases: Fourier transform infrared and 2H NMR spectroscopic studies of hydrocarbon chain conformation and orientational order in the liquid-crystalline state. (1994) (36)
Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. (2013) (36)
Lipid polymorphism and hydrocarbon order. (1990) (35)
Strategies for Optimizing Liposomal Doxorubicin (1990) (35)
Application of 31P-NMR saturation transfer techniques to investigate phospholipid motion and organization in model and biological membranes. (1980) (35)
pH gradients and membrane transport in liposomal systems. (1991) (35)
Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications. (2014) (34)
Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. (2007) (34)
A robust microfluidic technology and a new lipid composition for fabrication of curcumin-loaded liposomes: Effect on the anticancer activity and safety of cisplatin. (2019) (34)
Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles. (2017) (34)
Antibody conjugation methods for active targeting of liposomes. (2000) (34)
Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes (1996) (34)
Binding and Uptake of RGD-Containing Ligands to Cellular αvβ3 Integrins (2009) (33)
The influence of cholesterol 3-sulphate on phase behaviour and hydrocarbon order in model membrane systems. (1992) (33)
Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach. (2021) (33)
Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids (2018) (32)
Influence of vesicle size on complement-dependent immune damage to liposomes. (1986) (32)
The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. (1993) (32)
Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice (2004) (31)
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. (2008) (31)
Freeze-fracture of lipids and model membrane systems. (1989) (31)
An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. (1997) (30)
Phosphorus nuclear magnetic resonance of Acholeplasma laidlawii cell membranes and derived liposomes. (1976) (30)
Phosphatidic acid as a calcium ionophore in large unilamellar vesicle systems. (1984) (30)
CaV3.2 drives sustained burst‐firing, which is critical for absence seizure propagation in reticular thalamic neurons (2018) (29)
Cationic poly(ethyleneglycol) lipids incorporated into pre-formed vesicles enhance binding and uptake to BHK cells. (2001) (29)
Electron paramagnetic resonance in inhomogeneously broadened systems: A spin temperature approach (1976) (29)
Lipid requirements for coupled cytochrome oxidase vesicles. (1983) (28)
Progress towards a synthetic virus for systemic gene therapy. (1999) (28)
A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo (2016) (28)
31P-NMR studies on phospholipid structure in membranes of intact, functionally-active, rat liver mitochondria. (1982) (28)
Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide. (2019) (27)
Influence of lipid composition on the orientational order in Acholeplasma laidlawii strain B membranes: a deuterium NMR study. (1992) (27)
Production of limit size nanoliposomal systems with potential utility as ultra-small drug delivery agents (2015) (27)
"Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles" (2005) (26)
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. (2009) (26)
Introducing pharmacogenetic testing with clinical decision support into primary care: a feasibility study. (2016) (26)
Influence of plasma on the osmotic sensitivity of large unilamellar vesicles prepared by extrusion. (1994) (26)
31P-NMR studies of oriented phospholipid multilayers (1982) (26)
Incorporation of amphotericin B into large unilamellar vesicles composed of phosphatidylcholine and phosphatidylglycerol. (1990) (26)
Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function. (2019) (25)
Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations (1998) (25)
Capillary electrophoresis frontal analysis for characterization of alphavbeta3 integrin binding interactions. (2008) (25)
Spontaneous vesiculation of large multilamellar vesicles composed of saturated phosphatidylcholine and phosphatidylglycerol mixtures. (1988) (25)
Protein-liposome conjugates with defined size distributions. (1990) (24)
IGFBP2 is neither sufficient nor necessary for the physiological actions of leptin on glucose homeostasis in male ob/ob mice. (2014) (24)
An enhanced autogene-based dual-promoter cytoplasmic expression system yields increased gene expression (2004) (24)
Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents (2004) (24)
Modulation of the orientational order profile of the lipid acyl chain in the L alpha phase. (1990) (22)
Influence of vesicle size and oxidase content on respiratory control in reconstituted cytochrome oxidase vesicles. (1984) (22)
The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine (2009) (22)
Polymorphic phase behavior of unsaturated lysophosphatidylethanolamines: a 31P NMR and X-ray diffraction study. (1986) (22)
Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. (1983) (21)
Calcium enhances the transfection potency of stabilized plasmid-lipid particles. (2005) (21)
Aqueous two-phase polymer partitioning of lipid vesicles of defined size and composition. (1989) (21)
Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery (2020) (21)
Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo (2016) (21)
CHAPTER 4.2 – Designing therapeutically optimized liposomal anticancer delivery systems: Lessons from conventional liposomes (1998) (20)
Optimized Photoactivatable Lipid Nanoparticles Enable Red Light Triggered Drug Release. (2021) (20)
Chemical exchange between lamellar and non-lamellar lipid phases. A one- and two-dimensional 31P-NMR study. (1992) (20)
Fluorescent-labeled poly(ethylene glycol) lipid conjugates with distal cationic headgroups. (2000) (19)
STABILIZATION AND REGULATED FUSION OF LIPOSOMES CONTAINING A CATIONIC LIPID USING AMPHIPATHIC POLYETHYLENEGLYCOL DERIVATIVES (1998) (19)
Production of specifically deuterium labelled dioleoyl phospholipid species in gram quantities: A convenient synthesis of [C[11-2H2]oleic acid (1984) (18)
Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System (2022) (18)
Ca(2+)-induced fusion of phospholipid vesicles containing free fatty acids: modulation by transmembrane pH gradients. (1992) (18)
Membrane sorting: Endosome marker is fat not fiction (1998) (18)
Acyl chain orientational order in large unilamellar vesicles: comparison with multilamellar liposomes: a 2H and 31P nuclear magnetic resonance study. (1993) (18)
Characterization of cholesterol hemisuccinate and α-tocopherol hemisucccinate vesicles (1988) (18)
Influence of charge, charge distribution, and hydrophobicity on the transport of short model peptides into liposomes in response to transmembrane pH gradients. (1994) (18)
Ionophore-mediated loading of Ca2+ into large unilamellar vesicles in response to transmembrane pH gradients. (1994) (18)
Development and clinical applications of siRNA-encapsulated lipid nanoparticles in cancer (2014) (17)
Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. (1995) (17)
Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles. (2020) (17)
PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington’s disease (2021) (16)
Phospholipids as adjuncts for calcium ion stimulated release of chromaffin granule contents: implications for mechanisms of exocytosis. (1982) (16)
Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use (2019) (16)
Doxorubicin entrapped within liposome-associated antigens results in a selective inhibition of the antibody response to the linked antigen. (2000) (16)
Lipid nanoparticle delivery of glucagon receptor siRNA improves glucose homeostasis in mouse models of diabetes (2017) (16)
Correction to “Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core” (2012) (16)
Non-bilayer Lipids and the Inner Mitochondrial Membrane (1981) (16)
Deep Phenotyping by Mass Cytometry and Single-Cell RNA-Sequencing Reveals LYN-Regulated Signaling Profiles Underlying Monocyte Subset Heterogeneity and Lifespan (2020) (16)
The polymorphic phase behaviour of mixed phosphatidylserine-phosphatidylethanolamine model systems as detected by 31P-NMR. (1981) (15)
Use of a lipid nanoparticle system as a Trojan horse in delivery of gold nanoparticles to human breast cancer cells for improved outcomes in radiation therapy (2019) (15)
A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo (2004) (15)
Distal Cationic Poly(Ethylene Glycol) Lipid Conjugates in Large Unilamellar Vesicles Prepared by Extrusion Enhance Liposomal Cellular Uptake (2004) (14)
Platelet Distribution in Rabbits Following lnfusion of Liposomes (1989) (13)
Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo. (2016) (13)
Tunable pH-sensitive liposomes. (2004) (13)
Influence of cholesterol esters of varying unsaturation on the polymorphic phase preferences of egg phosphatidylethanolamine (1984) (12)
Protein-Membrane Interactions in the Complex Biological Milieu (1994) (12)
Development of high‐concentration lipoplexes for in vivo gene function studies in vertebrate embryos (2011) (12)
Phospholipid-Free Small Unilamellar Vesicles for Drug Targeting to Cells in the Liver. (2019) (12)
31P Nuclear magnetic resonance studies of cell membranes labelled with phosphonium phosphatidylcholine (1977) (12)
Polyfunctional properties of hybridoma lupus anticoagulant antibodies. (1987) (12)
Intervesicular exchange of lipids with weak acid and weak base characteristics: influence of transmembrane pH gradients. (1989) (12)
Physical studies on phosphonium phosphatidylcholine. A unique [31P]phosphorus nuclear-magnetic-resonance probe for model and biological membranes. (1975) (11)
Evidence for two pools of cholesterol in the Acholeplasma laidlawii strain B membrane: a deuterium NMR and DSC study. (1993) (11)
RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo (2017) (11)
Detergent-induced solubilization of cytochrome c oxidase as detected in a novel reconstituted system. (1984) (11)
Orientation of cytochrome c oxidase molecules in the two populations of reconstituted vesicles resolved by column chromatography on DEAE-Sephacryl. (1985) (10)
Chapter 9 Liposome Fusion (1997) (10)
A novel method for the efficient entrapment of calcium in large unilamellar phospholipid vesicles. (1990) (10)
Simultaneous, Single-Particle Measurements of Size and Loading Give Insights into the Structure of Drug-Delivery Nanoparticles. (2021) (9)
Preparation of reconstituted cytochrome oxidase vesicles with defined trans-membrane protein orientations employing a cytochrome c affinity column. (1985) (9)
Density Matching Multi-wavelength Analytical Ultracentrifugation to Measure Drug Loading of Lipid Nanoparticle Formulations. (2021) (9)
Polymorphic phase behavior of alpha-tocopherol hemisuccinate (1990) (9)
Sustained Depletion of FXIII-A by Inducing Acquired FXIII-B Deficiency. (2020) (9)
Factors limiting autogene‐based cytoplasmic expression systems (2005) (9)
Detection of surface charge-related properties in model membrane systems by aqueous two-phase partition. (1989) (8)
Generation and characterization of iron- and barium-loaded liposomes. (1992) (8)
Commentary: Liposomes by Accident (2000) (8)
N-succinyldioleoylphosphatidylethanolamine: structural preferences in pure and mixed model membranes. (1988) (8)
The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN (2008) (8)
Protective Effect of Edaravone against Cationic Lipid-Mediated Oxidative Stress and Apoptosis. (2021) (7)
Lipid Polymorphism, Lipid Asymmetry and Membrane Fusion (1988) (6)
Clinical and Preclinical Pharmacology of Liposomal Vincristine (2000) (6)
Membrane Fusion and Lipid Polymorphism (1985) (5)
Encapsulation of Drugs Within Liposomes by pH-Gradient Techniques (2016) (5)
Altering the intra-liver distribution of phospholipid-free small unilamellar vesicles using temperature-dependent size-tunability. (2021) (5)
Improved Liver Delivery of Primaquine by Phospholipid-Free Small Unilamellar Vesicles with Reduced Hemolytic Toxicity. (2021) (4)
Structural Properties of Inverted Hexagonal Phase: A Hybrid Computational and Experimental Approach. (2020) (4)
Dioleoylphosphatidylethanolamine-Dioleoylphosphatidylcholine Systems: A (1982) (4)
A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity (2007) (4)
A model approach for assessing liposome targeting in vivo (1995) (4)
Comparison of the Orientational Order of Lipid Chains in the La and HII Phases ? (2001) (4)
Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies. (2022) (4)
PREPARATION OF STREPTAVIDIN-LIPOSOMES FOR USE IN LIGAND-SPECIFIC TARGETING APPLICATIONS (2000) (4)
Author Correction: The current landscape of nucleic acid therapeutics (2021) (4)
Vincristine sulfate liposomes injection concentrates vincristine in tumor tissue and bone marrow of tumor-bearing mice (2007) (4)
Magnetic Filtration of Vesicles Containing Iron-Dextran Particles (1988) (4)
Detection of protein-free lipoprotein analogues with an apolar lipid core by freeze-etch electron microscopy. (1987) (4)
Vinorelbine liposomes injection results in greater tumor drug exposure compared to conventional vinorelbine in tumor-bearing nude mice (2007) (4)
Structural and Functional Aspects of Nonbilayer Lipids (1982) (3)
Lipid Asymmetry, Clustering and Molecular Motion in Biological Membranes and Their Models (1977) (3)
FAM13A as potential therapeutic target in modulating TGF-beta-induced airway tissue remodeling in COPD. (2021) (3)
Investigation of factors responsible for cell line cytoplasmic expression differences (2005) (3)
13 Synthetic Virus Systems for Systemic Gene Therapy (2000) (3)
Synthesis and Characterization of Hybrid Lipid Nanoparticles Containing Gold Nanoparticles and a Weak Base Drug. (2022) (3)
Role of drug delivery technologies in the success of COVID-19 vaccines: a perspective (2022) (3)
Effects of Anesthetics on Lipid Polymorphism (2000) (3)
Modelling the biological membrane. (1987) (3)
Use of transmembrane pH gradients and A23187 to produce dense iron liposomes. (1990) (2)
Lipid encapsulation promotes co-localization of methylated CpG ODN and TLR9 in late endosomes: A new model for the immunostimulatory activity of CpG DNA (2008) (2)
Value-based healthcare delivery through metabolomics-based personalized health platform (2020) (2)
"Diffusible-PEG-lipid stabilized plasmid lipid particles". (2005) (2)
La Reunion Island (21S, 55.5E) SHADOZ/NDACC station: First re-processed ozonesonde data and comparisons with lidar measurementsat the Maïdo Observatory (2016) (2)
Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice. (2007) (2)
Characterization of cholesterol hemisuccinate and alpha-tocopherol hemisuccinate vesicles. (1988) (2)
OUTSIDE-INSIDE D ISTRIBUTIONS AND SIZES OF M IXED PHOSPHATI- DYLCHOLINE-CHOLE STEROL VESICLES (1976) (2)
Lipid Nanoparticle Mediated Silencing of Osteogenic Suppressor GNAS Leads to Osteogenic Differentiation of Mesenchymal Stem Cells In Vivo. (2022) (1)
Suppression of fibrin(ogen)-driven pathologies through controlled knockdown by lipid nanoparticle delivery of siRNA. (2021) (1)
Developing serum-stabilized cationic liposome-dna particles for gene therapy by preformed vesicles and ethanol method (2000) (1)
Medical Applications of Lipid Nanoparticles (2014) (1)
Transfection of BHK cell by serum-stabilized cationic liposome-DNA particles (2000) (1)
Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model (2015) (1)
Lipid Polymorphism , ” in The Encyclopedia of Nuclear Magnetic Resonance (2000) (1)
Encapsulation of Nucleic Acid–Based Therapeutics (2016) (1)
THE ROLE OF SURFACE CHARGE IN THE ACTIVATION AND ALTERNATIVE PATHWAYS OF COMPLEMENT (2001) (1)
The Partitioning of Liposomes of Defined Size and Composition (1989) (1)
Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy. (2022) (1)
Lipid particles for delivery of nucleic acids (2010) (0)
ENHANCED RETENTION OF BOACTIVE AGENTS (2017) (0)
Aminolpidos improved and methods for delivery of nucleic acids (2009) (0)
Light-Activated siRNA Endosomal Release (LASER) by Porphyrin Lipid Nanoparticles. (2023) (0)
Hepatocyte-targeted delivery of imiquimod reduces hepatitis B virus surface antigen. (2022) (0)
Patent Number : 5 , 795 , 589 45 ) Date of Patent : * Aug . 18 , 1998 (2017) (0)
COMMENTARY : LIPOSOMES BY ACCIDENT 1 (0)
MP46-15 LIPID NANOPARTICLE SIRNA POTENTLY SILENCES CLUSTERIN AND DELAYS PROGRESSION WHEN COMBINED WITH ANDROGEN RECEPTOR CO-TARGETING IN ENZALUTAMIDE RESISTANT PROSTATE CANCER (2015) (0)
Target liposomes, and methods for coupling of liposome-proteins (1990) (0)
Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use (2019) (0)
Dehydrated liposome pharmaceutical preparation (1994) (0)
Procede d'administration d'agents therapeutiques, incluant l'anti-sens avec dosage repetitif (1999) (0)
Formulations of liposomal antineoplastic agents with high drug-lipid ratio (1989) (0)
Abstract 1970: Liposomal nanoparticle siRNA delivery systems forin vivosilencing of the androgen receptor in human prostate cancer (2012) (0)
On the Influence of Nucleic Acid Backbone Modifications on Lipid Nanoparticle Morphology. (2022) (0)
Development of Lipid-Based Drug Delivery Systems for Gene Therapy: Physicochemical Characterization of Charged Lipid Interactions (2016) (0)
EndosomesAbility To Colocalize with TLR9 in Late Oligodeoxynucleotide Is Dependent on Their Unmethylated and Methylated CpG The Immunostimulatory Activity of (2010) (0)
drug-lipid systems low toxicity. (1988) (0)
Effect of lipid nanoparticle siRNA delivery systems on silencing clusterin and progression in enzalutamide resistant prostate cancer in vivo. (2015) (0)
Fusogenic liposomes and methods of manufacture and use. (1994) (0)
Development of a Child-Friendly Oral Drug Formulation Using Liposomal Multilamellar Vesicle Technology. (2022) (0)
Preparation of therapeutic agents for lipid encapsulation. (2000) (0)
Polyanionic polymers with improved fusogenfähigkeit (1999) (0)
The NanoAssemblr TM Platform : Microfluidics-based Manufacture of Limit Size Lipid Nanoparticles for Drug and Nucleic Acid Delivery (2013) (0)
We Acknowledge Support for This Project from Nih Grants Gm40162 and Ca87630 and from Nsf Grant Cdr-8622201 and Thank Our Collaborators and Co-workers, [7] Tunable Ph-sensitive Liposomes (2004) (0)
Optimizing Drug Release: Bilayer to Inverted Hexagonal Phase Transition of Cationic XTC2 and Anionic DSPS Lipid System is Influenced by pH, Temperature, and Salt Concentration (2014) (0)
Sterically stabilized liposomal doxorubicin exhibits reduced passive tumor targeting efficiency in mice bearing Lewis Lung Carcinoma (1996) (0)
Developing Transient Gene Therapies to Decrease the Stability of Thrombi for Coagulopathy and Thrombosis (2020) (0)
Loading of medicine into liposome (1994) (0)
614. Microfluidic Manufacture of RNA-Lipid Nanoparticles Leads to Highly Efficient Delivery of Potent Nucleic Acid Therapeutics for Controlling Gene Expression (2016) (0)
PHOSPHATIDIC ACID AS A CALCIUM I O N O P H O R E IN LARGE VESICLE SYSTEMS (2002) (0)
A Whole-Cell Binding Assay for Testing the Targeting Potential of Cyclic Peptide Ligands (2006) (0)
Morphological Behavior of Liposomes and Lipid Nanoparticles. (2023) (0)
Loading weakly basic drug in liposomes by ionophores. (1997) (0)
Mice Ratio on the Biological Activity of Liposomal Doxorubicin in Influence of Vesicle Size , Lipid Composition , and Drug-to-Lipid Updated Version (2006) (0)
Liposomes containing Guanidinaminoglycosid (1987) (0)
Preparation d'agents therapeutiques a encapsulation lipidique (2000) (0)
NMR TO MODEL AND BIOLOGICAL MEMBRANE SYSTEMS (2000) (0)
P14. Abstract Title: Modulating Fibrinolysis using siRNA against Coagulation Factor XIII (2019) (0)
X-ray Diffraction Study of the Polymorphic Behavior of N-Methylated Dioleoylphosphatidylethanolaminet (2001) (0)
Preparation antibiotique a base de liposomes (1987) (0)
1999 Referees (1999) (0)
Current Membrane Research Membrane Research: Classic Origins and Current Concepts A. L. Muggleton-Harris (1982) (0)
Tissue microenvironment and cellular imaging (2017) (0)
Modelling of the Interaction between Cationic Lipid Dlin-Kc2-Dma (XTC2) and Anionic Lipid Distearoylphosphatidylserine (DSPS) (2014) (0)
High-throughput sequencing defines donor and recipient HLA B-cell epitope frequencies for prospective matching in transplantation (2021) (0)
Extrusion methods for preparing liposomes (1986) (0)
STRUCTURAL AND FUNCTIONAL ASPECTS OF NON-BILAYER LIPIDS IN MEMBRANES (1981) (0)
LIPID POLYMORPHISM AND THE OCCURRENCE OF NON-BILAYER PHASES IN MODEL AND BIOLOGICAL MEMBRANES * (2000) (0)
Reduction of rate of releasing medicine from liposome (1994) (0)
Methods for preparing liposomes and method for increasing the homogeneity of a population of liposomic (1986) (0)
314. mRNA Production is the Major Factor Limiting Autogene-Based Cytoplasmic Expression (2004) (0)
DOPG from the inner to the outer monolayer of 100 nm diameter DOPC : DOPG ( 9 : 1 , mol : mol ) LUVs . Previous studies with DOPC : DOPG (2005) (0)
LIPOSOMES, DIMITRI PAPAHADJOPOULOS, AND US (1995) (0)
The NanoAssemblr TM Platform : Scalable , Microfluidics-based Manufacture of siRNA Lipid Nanoparticles (2014) (0)
Ionoforformidlet loading of liposomes with weakly basic drugs (1997) (0)
Multilamellar liposome with improved einschliessungswirkung. (1986) (0)
Characterization of Phases and Interactions Among Lipids Involved in Drug Delivery: An NMR and Small-Angle X-Ray Scattering Study (2018) (0)
Strategies to increase the drug retention, plasma exposure and antitumor activity of liposomal topotecan (2006) (0)
Method for coupling liposomes. (1992) (0)
Electron paramagnetic resonance of phosphorus doped silicon in the intermediate impurity concentration range (1972) (0)
Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures (2023) (0)

This paper list is powered by the following services:

Other Resources About Pieter Cullis

en.wikipedia.org

What Schools Are Affiliated With Pieter Cullis?

Pieter Cullis is affiliated with the following schools:

Pieter Cullis's Academic­Influence.com Rankings

Pieter Cullis's Degrees

Why Is Pieter Cullis Influential?

Pieter Cullis's Published Works

Published Works

Other Resources About Pieter Cullis

What Schools Are Affiliated With Pieter Cullis?

Pieter Cullis's AcademicInfluence.com Rankings